Professor Jun Ma: Advancing Frontiers, Updating Guidelines, and Accelerating the Globalization of Hematologic Cancer Treatment

Professor Jun Ma: Advancing Frontiers, Updating Guidelines, and Accelerating the Globalization of Hematologic Cancer Treatment

From January 17 to 19, 2025, the Chinese Society of Clinical Oncology (CSCO) Leukemia, Lymphoma, and Multiple Myeloma Expert Committee Meeting & 2025 CSCO Hematologic Oncology Conference was held in the scenic city of Haikou. This high-profile event brought together leading experts from China and abroad to discuss the latest advances in leukemia, lymphoma, and multiple myeloma, covering both fundamental research and clinical applications. The conference also addressed key challenges in diagnosis and treatment, fostering in-depth discussions among specialists.
Dr. Zefei Jiang：Toripalimab Plus Nab-Paclitaxel in Metastatic or Recurrent Triple-Negative Breast Cancer: A Randomized Phase 3 Trial

Dr. Zefei Jiang：Toripalimab Plus Nab-Paclitaxel in Metastatic or Recurrent Triple-Negative Breast Cancer: A Randomized Phase 3 Trial

In a significant advancement in cancer research, Dr. Zefei Jiang and his team from The Fifth Medical Center of  Chinese PLA General Hospital published the article "Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial" in Nature Medicine(IF=83) on January 1, 2024. This pivotal study investigates the efficacy and safety of combining toripalimab, an immune checkpoint inhibitor, with nab-paclitaxel in treating metastatic or recurrent triple-negative breast cancer (TNBC). TNBC, marked by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression, presents limited treatment options and a poor prognosis. The study addresses the urgent need for more effective therapies for this aggressive breast cancer subtype.